Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 145 open-label extension for long-term safety and efficacy in hypercholesterolaemia
NL-OMON40037Phase 2Active, not recruiting
- Sponsor
- Amgen
- Start
- Jan 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of evolocumab in hypercholesterolemia, sponsored by Amgen. Primary endpoint: Adverse events. Started Jan 2012; status: active, not recruiting.
02
Drugs
evolocumab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NL-OMON40037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40037.